Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection

被引:75
|
作者
Micallef, Joelle [1 ]
Soeiro, Thomas [1 ]
Jonville-Bera, Annie-Pierre [2 ]
机构
[1] Aix Marseille Univ, AP HM, INSERM, Serv Pharmacol Clin,Ctr Reg Pharmacovigilance,UMR, 264 Rue St Pierre, F-13005 Marseille, France
[2] Ctr Hosp Reg Univ Tours, Ctr Reg Pharmacovigilance, Serv Pharmacosurveillance, F-37000 Tours, France
来源
THERAPIE | 2020年 / 75卷 / 04期
关键词
Anti-inflammatory agents; non-steroidal; Infections; Respiratory tract infections; Superinfection; COVID-19; Pharmacovigilance; Pharmacoepidemioiogy; RISK-FACTORS; NECROTIZING FASCIITIS; VIMENTIN EXPRESSION; MUSCLE INJURY; IBUPROFEN; CHILDREN; CYCLOOXYGENASE; NUCLEOPROTEIN; COMPLICATIONS; INHIBITORS;
D O I
10.1016/j.therap.2020.05.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Non-steroidal anti-inflammatory drugs (NSAIDs) have an optional prescription status that has resulted in frequent use, in particular for the symptomatic treatment of fever and non-rheumatic pain. In 2019, a multi-source analysis of complementary pharmacological data showed that using NSAIDs in these indications (potentially indicative of an underlying infection) increases the risk of a severe bacterial complication, in particular in the case of lung infections. First, the clinical observations of the French Pharmacovigilance Network showed that severe bacterial infections can occur even after a short NSAID treatment, and even if the NSAID is associated with an antibiotic. Second, pharmacoepidemiological studies, some of which minimized the protopathic bias, all converged and confirmed the risk. Third, experimentat in vitro and in vivo animal studies suggest several biological mechanisms, which strengthens a causal link beyond the well-known risk of delaying the care of the infection (immunomodulatory effects, effects on S. pyogenes infections, and reduced antibiotics efficacy). Therefore, in case of infection, symptomatic treatment with NSAIDs for non-severe symptoms (fever, pain, or myalgia) is not to be recommended, given a range of clinical and scientific arguments supporting an increased risk of severe bacterial complication. Besides, the existence of a safer drug alternative, with paracetamol at recommended doses, makes this recommendation of precaution and common sense even more legitimate. In 2020, such recommendation is more topical than ever with the emergence of COVID-19, especially since it results in fever, headaches, muscular pain, and cough, and is further complicated with pneumopathy, and given experimental data suggesting a link between ibuprofen and the level of expression of angiotensin-converting enzyme 2. (C) 2020 Societe francaise de pharmacologie et de therapeutique. Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:355 / 362
页数:8
相关论文
共 50 条
  • [1] Non-steroidal anti-inflammatory drugs and covid-19
    Little, Paul
    BMJ-BRITISH MEDICAL JOURNAL, 2020, 368
  • [2] Prostaglandins and non-steroidal anti-inflammatory drugs in Covid-19
    Al-Kuraishy, Hayder M.
    Al-Gareeb, Ali, I
    Al-Maiahy, Thabat J.
    Alexiou, Athanasios
    Mukerjee, Nobendu
    Batiha, Gaber El-Saber
    BIOTECHNOLOGY AND GENETIC ENGINEERING REVIEWS, 2022, 40 (04) : 3305 - 3325
  • [3] Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19
    Robb, Calum T.
    Goepp, Marie
    Rossi, Adriano G.
    Yao, Chengcan
    BRITISH JOURNAL OF PHARMACOLOGY, 2020, 177 (21) : 4899 - 4920
  • [4] Do non-steroidal Anti-inflammatory Drugs favor COVID-19?
    Lorenz, Judith
    AKTUELLE RHEUMATOLOGIE, 2021, 46 (05)
  • [5] The use of non-steroidal anti-inflammatory drugs (NSAIDs) in COVID-19
    Kushner, Pamela
    McCarberg, Bill H.
    Grange, Laurent
    Kolosov, Anton
    Haveric, Anela Lihic
    Zucal, Vincent
    Petruschke, Richard
    Bissonnette, Stephane
    NPJ PRIMARY CARE RESPIRATORY MEDICINE, 2022, 32 (01)
  • [6] The use of non-steroidal anti-inflammatory drugs (NSAIDs) in COVID-19
    Pamela Kushner
    Bill H. McCarberg
    Laurent Grange
    Anton Kolosov
    Anela Lihic Haveric
    Vincent Zucal
    Richard Petruschke
    Stephane Bissonnette
    npj Primary Care Respiratory Medicine, 32
  • [7] The Association of Non-Steroidal Anti-Inflammatory Drugs with COVID-19 Severity and Mortality
    Samimagham, Hamid Reza
    Arabi, Mohsen
    Hooshyar, Dariush
    KazemiJahromi, Mitra
    ARCHIVES OF CLINICAL INFECTIOUS DISEASES, 2020, 15 (04): : 1 - 5
  • [8] Non-steroidal anti-inflammatory drugs and clinical outcomes in patients with COVID-19
    Zhang, Jing
    Sheng, Hongguang
    Tang, Xiaoyi
    Xia, Panpan
    Li, Zhangwang
    Xu, Minxuan
    Ma, Jianyong
    Shen, Yunfeng
    Yu, Peng
    Liu, Xiao
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2022, 12
  • [9] Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID)
    Giollo, Alessandro
    Adami, Giovanni
    Gatti, Davide
    Idolazzi, Luca
    Rossini, Maurizio
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (02)
  • [10] Non-steroidal anti-inflammatory drug use in COVID-19
    不详
    LANCET RHEUMATOLOGY, 2021, 3 (07): : E465 - E465